Morgan Stanley began coverage on shares of TherapeuticsMD Inc (NYSEMKT:TXMD) in a research report released on Friday morning, StockTargetPrices.com reports. The brokerage issued an equal weight rating and a $6.00 target price on the specialty pharmaceutical company’s stock.

TXMD has been the subject of a number of other research reports. Cantor Fitzgerald reiterated an overweight rating and set a $33.00 target price on shares of TherapeuticsMD in a research note on Thursday, May 11th. BidaskClub upgraded shares of TherapeuticsMD from a hold rating to a buy rating in a research note on Friday. Oppenheimer Holdings, Inc. upgraded shares of TherapeuticsMD from a market perform rating to an outperform rating in a research note on Tuesday, July 11th. Finally, Stifel Nicolaus restated a buy rating and issued a $20.00 price objective on shares of TherapeuticsMD in a research note on Thursday, May 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $18.93.

Shares of TherapeuticsMD (NYSEMKT TXMD) opened at 6.53 on Friday. TherapeuticsMD has a 52-week low of $3.50 and a 52-week high of $8.30. The stock has a 50 day moving average price of $5.87 and a 200-day moving average price of $5.57. The firm’s market cap is $1.33 billion.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/12/therapeuticsmd-inc-txmd-now-covered-by-morgan-stanley.html.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Stock Target Prices

Analyst Recommendations for TherapeuticsMD (NYSEMKT:TXMD)

Receive News & Stock Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related stocks with our FREE daily email newsletter.